『2 Minutes with Joey - NVS Stock News』のカバーアート

2 Minutes with Joey - NVS Stock News

2 Minutes with Joey - NVS Stock News

著者： 2 Minutes with Joey
無料で聴く

Two minutes with Joey on Novartis (NVS) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.Copyright 2 Minutes with Joey 社会科学
エピソード
  • NVS Today - Aug 13: Small Dip After FDA News

    NVS Today - Aug 13: Small Dip After FDA News
    2026/08/13
    Hey there! It’s Joey, your friendly neighborhood investor. I’ve been in the game for a while, and today I’m breaking down Novartis, ticker NVS. So, how did it do? Well, it had a bit of a rough day, ending down just a smidge—like, barely moving, just a 0.04% dip.

    So, what went down? Well, the stock kinda got smoked after some news hit about Pluvicto, which is one of their cancer treatments. The FDA gave a thumbs up for a combo approval, but it looks like traders weren’t too thrilled, and they hit that sell button fast. It’s like when your favorite band releases a new song, and it’s just not what you expected.

    Now, let’s talk about why all this happened. First off, Novartis did win a court challenge in the UK related to its Entresto patent, which is a win for them, but the market seemed to shrug it off. Maybe folks were more focused on that Pluvicto news. Plus, I saw some reports saying that some big investors, like Triasima and Mission Wealth Management, are making moves with their shares—some buying more, others trimming down. It’s like a game of musical chairs where no one wants to be left standing when the music stops.

    And speaking of the horizon, Novartis is working on optimizing its supply chain, which could be a big deal moving forward. If they nail that, it might help them streamline operations and improve profits.

    So, yeah, today was a bit of a bummer for Novartis, but there’s always something brewing in the background. Just remember, I’m here to keep you in the loop, but this isn’t financial advice. Just some friendly chatter about the stock world. Catch you later!
    続きを読む 一部表示
    1 分
  • NVS Today - Aug 12: Weaker Earnings Forecasts

    NVS Today - Aug 12: Weaker Earnings Forecasts
    2026/08/12
    Hey there! It's Joey here, your pal who’s been in the investing game for a while. Today, we're talking about Novartis, and it was a bit of a red day, dropping about 1.2%. Ouch!

    So, what went down? The stock got smoked today, and honestly, it felt like a slow bleed. It opened up okay but just kinda drifted downwards throughout the day. Nothing too wild in the volume, just your usual trading action.

    Now, let’s get into why this happened. The big news is that Erste Group Bank threw out a forecast saying Novartis is looking at weaker earnings ahead. That kind of news? Yeah, it makes investors nervous. People hit the sell button fast when they hear stuff like that, especially when the market is already a bit shaky. Plus, there’s been chatter about layoffs in the biotech space, which has folks wondering about the stability of companies like Novartis. And then, there’s that deal with Dr. Reddy’s in India that’s set to end soon, which adds to the uncertainty. All these factors piled up and led to some selling pressure.

    On a slightly brighter note, Novartis is working on optimizing its supply chain. That’s a solid move in the long run, but right now, it feels overshadowed by the earnings forecast.

    To wrap it up, Novartis had a rough day, mainly due to some weak earnings chatter and industry concerns. Just remember, this info is for your entertainment and to keep you in the loop, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • NVS Today - Aug 11: Earnings Concerns Loom

    NVS Today - Aug 11: Earnings Concerns Loom
    2026/08/11
    Hey there! It's Joey, your friendly longtime investor, here to break down the day for you. Today we’re looking at Novartis, and it wasn’t a great day for them—stock dipped about one percent.

    So, what went down? Novartis started the day steady but ended up sliding. Yeah, that one stung a bit. It’s like when you think you’re safe, and then bam, the stock just gets a little beat up.

    Now, the chatter around why this happened is mostly linked to some forecasts from Erste Group Bank. They’re saying Novartis might be facing weaker earnings ahead. That kind of news can hit hard, you know? Investors don’t like uncertainty, so people started hitting the sell button fast. Also, there’s been some talk about how the company is optimizing its supply chain, but that didn’t seem to lift the mood much today.

    On the horizon, there’s a buzz about Novartis’s ongoing earnings and guidance. Even with the dip, some folks think there’s still support from that side of things.

    So, to wrap it up, Novartis had a rough day, mainly due to those earnings forecasts. Just a reminder, I’m here to share info and keep it fun, not to give financial advice. Catch you later!
    続きを読む 一部表示
    1 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません